Clinical Trial

A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated November 12, 2024 (before its estimated April 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is a multicenter, open-label, dose-finding/efficacy-expanding Phase IB/II clinical trial to evaluate SHR-A2102 in combination with adebelimab in combination with SHR-8068 in patients with locally advanced or metastatic non-small cell lung cancer. The study consists of two phases: Phase IB to explore the safety/tolerability of SHR-A2102 in combination with adebelimab in combination with SHR-8068 in patients with locally advanced or metastatic non-small cell lung cancer; Phase II: To explore the efficacy of SHR-A2102 in combination with adebelimab in combination with SHR-8068 in patients with locally advanced or metastatic non-small cell lung cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-09-06.
Status change: Not Yet Recruiting → Recruiting 2024-11-07
Trial Details
NCT Number NCT06589778
Lead Sponsor Shanghai Hengrui Pharmaceutical Co., Ltd.
Conditions Non-Small Cell Lung Cancer
Enrollment 124 participants
Start Date 2024-09-27
Primary Completion 2026-04-30 (estimated)
Study Completion 2026-04-30 (estimated)
Updated on ClinicalTrials.gov 2024-11-12